Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. CSL Limited
  6. News
  7. Summary
    CSL   AU000000CSL8

CSL LIMITED

(CSL)
  Report
End-of-day quote. End-of-day quote Australian Stock Exchange - 09/16
308.32 AUD   +1.13%
09/12Australia's NSW state says coronavirus vaccination pace slows
RE
09/12CSL : Positive COVID-19 Case at Broadmeadows
PU
09/02CSL : Annual Report
PU
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

CSL : Seqirus says can supply 60 mln doses of influenza vaccines for U.S. flu season

07/27/2021 | 01:26pm EDT

July 27 (Reuters) - Vaccine maker Seqirus, a part of Australia-based biotech company CSL ltd, said on Tuesday it has started shipping its influenza vaccines to the United States and can supply about 60 million doses of its shots for the upcoming flu season.

The company, one of the largest vaccine providers in the world, is ramping up production to meet the demand seen during the 2020-21 season, when a record 193.8 million doses of influenza vaccines were distributed in the U.S.

Flu activity was unusually low throughout the 2020-2021 flu season both in the United States and globally, likely due to COVID-19 mitigation measures like wearing face masks as well as high influenza vaccination rates, according to health agencies.

Experts, however, have cautioned that the upcoming flu season for 2021-22 might see higher cases as COVID-19 related restrictions ease. Flu season occurs in the fall and winter, with flu activity generally peaking between December to February.

"A continued focus on influenza vaccination is critically important because, while rates of influenza were generally low last season, we cannot assume this will be the case during the coming year and we need to be prepared," Chief Medical Officer Gregg Sylvester said in a statement.

Seqirus currently offers three types of influenza vaccines that cover a wide age group - from children as young as six months of age to adults 65 years and older.

(Reporting by Mrinalika Roy in Bengaluru; Editing by Shailesh Kuber)


© Reuters 2021
All news about CSL LIMITED
09/12Australia's NSW state says coronavirus vaccination pace slows
RE
09/12CSL : Positive COVID-19 Case at Broadmeadows
PU
09/02CSL : Annual Report
PU
09/02CSL LIMITED : Ex-dividend day for final dividend
FA
09/01Australian shares drop over 1% on BHP losses, COVID-19 worries
RE
08/31Banks, miners drive Australian shares lower ahead of GDP data
RE
08/30Australian shares rise on tech, miners boost; banks cap gains
RE
08/19Seqirus Announces Investment in Next-Generation Influenza Vaccine Technology,..
CI
08/18CSL : Uncertainty Prevails For CSL
AQ
08/17CSL's Plasma Collections on Track to Exceed Pre-Pandemic Levels, CEO Says
DJ
More news
Analyst Recommendations on CSL LIMITED
More recommendations
Financials (USD)
Sales 2022 10 600 M - -
Net income 2022 2 245 M - -
Net Debt 2022 3 708 M - -
P/E ratio 2022 45,7x
Yield 2022 0,96%
Capitalization 102 B 102 B -
EV / Sales 2022 10,0x
EV / Sales 2023 9,12x
Nbr of Employees 25 000
Free-Float 99,9%
Chart CSL LIMITED
Duration : Period :
CSL Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CSL LIMITED
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 224,80 $
Average target price 227,99 $
Spread / Average Target 1,42%
EPS Revisions
Managers and Directors
Paul Roger Perreault Chief Executive Officer, Executive Director & MD
Joy Carolyn Linton Chief Financial Officer
Brian Anthony McNamee Chairman
Andrew Cuthbertson Chief Scientific Officer & Executive Director
William Mezzanotte Chief Medical Officer, EVP & Head-R&D
Sector and Competitors